Australian Bionic Eye Developer Sets Sights To Enter Market By 2020
Australia's Bionic Vision Technologies (BVT) has raised AUS$23m ($18m) from Hong Kong-based investors, China Huarong International Holdings Ltd and State Path Capital Limited, to develop and commercialize its retinal implant device. The technology could reach the market 3-5 years from now.
You may also be interested in...
Competition in the retinal implant market heats up as Pixium CE marks its second-generation bionic vision system, designed to offer key advantages including higher resolution and explantability.
By CE-marking the Alpha AMS second-generation subretinal implant, Retina Implant has further widened the gap between itself and its rivals who are also developing devices to restore vision in patients blinded by degenerative retinal diseases such as retinitis pigmentosa.
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.